It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

IJCRIMPH: Pioglitazone induced weight changes in type 2 diabetic patients
 
    .
   
  Home  |  About Journal  |  Browse Articles  |  Editorial Board  |  Authors Guidelines  |  Submit Article  |  FAQ  |  Contact  
   

IJCRIMPH Articles:

Pioglitazone induced weight changes in type 2 diabetic patients IJCRIMPH articles are provided for free based on an Open Access policy
'
International Journal of Collaborative Research on Internal Medicine & Public Health, 2011 - Vol. 3 No. 6

Author(s): Sayantani Ghosh *, Saugat Dey

B S Medical College, India

* Corresponding author


Abstract:

Background: Pioglitazone, a member of the thiazolidinedione drug family, with hypoglycemic action, is widely used for the therapy of type 2 diabetic patients.

Aims and Objectives: The effect of pioglitazone on body weight was investigated and the effects of monotherapy and combinations with other hypoglycemic agents were compared.

Methodology: A prospective study on 379 type 2 diabetic cases, who were being given pioglitazone for the first time, as either monotherapy or in combination with other oral hypoglycemic agents or insulin. Parameters were analyzed by Kruskal-Wallis test, considering p <0.05 as significant.

Results: Pioglitazone therapy resulted in weight gain, especially in females, although triglyceride and lipoprotein levels were not adversely affected. Concomitant use of pioglitazone along with insulin or any of the sulfonylurea group of drugs accounted for more weight gain; (2.57±1.4 kg) and (2.31±1.2 kg) respectively; than that by pioglitazone alone (2.23±1.3 kg). However pioglitazone combination therapy with metformin and alpha glycosidase inhibitors revealed lower weight gain: (0.31±0.2 kg) and (0.16±0.4 kg) respectively. Higher doses of pioglitazone were associated with more important weight gain.

Limitations of the study:

1.   The study is an open-label prospective observational study and not a double blinded randomized controlled trial.

2.    Long term changes in weight were not assessed, as the mean follow up period was only 6 months.

3.    There were very few patients (only 28) on pioglitazone monotherapy.

 

Conclusions: Pioglitazone increases body weight, although less than other thiazolidinediones. Hence it should not be indiscriminately used in high doses and when used, it should be supplemented with metformin and alpha glycosidase inhibitors.


Keywords:
Pioglitazone, thiazolidinedione, body weight, Type- 2 Diabetes Mellitus, insulin, oral hypoglycemic agents
 

Conflicts of Interest: None

How to cite this article:

Ghosh S, Dey S. Pioglitazone induced weight changes in type 2 diabetic patients. International Journal of Collaborative Research on Internal Medicine & Public Health. 2011; 3(6):534-540.

 
Article Options:
Abstract
Full Text (PDF)
Cite this article
Track Citations
Published Online: 30 June 2011
 
Article Sharing Tools:
Email to a friend:  Email
 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 

________________________________________________

All rights reserved. © 2008-2011
International Online Medical Council (IOMC)
Locations of visitors to this page
Free counter and web stats